Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10553

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Tophaceous Gout
Interventions: Allopurinol, Dotinurad; Drug
Lead sponsor: Crystalys Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 96
States / cities: Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 86 more

Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
Interventions: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 0 Years to 38 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more

Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 43
States / cities: Duarte, California • Irvine, California • La Jolla, California + 37 more

Conditions: Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Interventions: Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System, SAVR; Device
Lead sponsor: JenaValve Technology, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 40
States / cities: Burlingame, California • La Jolla, California • Los Angeles, California + 32 more

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 34
States / cities: Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 29 more

Conditions: Focal Seizures
Interventions: CBD-OS; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose; Other · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more

Conditions: Tuberous Sclerosis Complex, Epilepsy
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: Darcy Krueger; Other
Eligibility: 1 Day to 6 Months
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 5 more

Conditions: Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 276
States / cities: Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more

Conditions: Neurofibromatosis 1, Plexiform Neurofibromas
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years and older
Enrollment: 476 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Sickle Cell, Diabetes, Cancer, Cardiovascular Disease, Genetic Screening
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 3
States / cities: Bethesda, Maryland • Cincinnati, Ohio • Lewisburg, Pennsylvania

Conditions: Aortic Valve Regurgitation, Aortic Valve Disease Mixed
Interventions: J-Valve Transfemoral (TF) System; Device
Lead sponsor: JC Medical, Inc., an affiliate of Edwards Lifesciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more

Clinical trials in Cincinnati, Ohio

Filter and sort this location

Live official records

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Developing the Family Map: Looking at Communal Coping

J-Valve Transfemoral Pivotal Study